Search - Prime Therapeutics - Portal

411 Results for GLP-1 Pipeline Update

Star Tribune: Study: Trendy weight-loss drugs could be a waste for Minnesotans, health plans

Star Tribune

PA Sub-Categories: GLP-1 Prime Article: In the News
Business Insider: Inside your company's struggle over whether to pay for hot, new weight-loss drugs

Business Insider

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Exclusive: New data show most US patients now stay on Wegovy, Zepbound after a year

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
NBC News: Most people stop using Wegovy and Ozempic after 2 years, analysis finds

NBC News: Patients weren't asked why they quit taking the weight loss drugs

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Weight-loss drugs didn't curb health costs within two years

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
Washington Post: Weight-loss drugs are supposed to be forever. Until they run out.

Washington Post: Doctors and patients struggle with starting and stopping medications with little guidance.

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Exclusive: Most patients using weight-loss drugs like Wegovy stop within a year, data show

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Exclusive: Most patients stop using Wegovy, Ozempic for weight loss within two years

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News

Page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
Page 21
Page 22
Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- Page 39
- Page 40
- Page 41
- Page 42
- Page 43
Page 52

Login Portals

Compliance / Legal

Company

© 2025 Prime Therapeutics LLC